Tachycardia-induced cardiomyopathy: A reversible form of left ventricular dysfunction

https://doi.org/10.1016/0002-9149(86)90836-2Get rights and content

Abstract

Eight patients, aged 5 to 57 years, with uncontrolled symptomatic tachycardia for 2.5 to 41 years (mean 15) and significant left ventricular (LV) dysfunction in the absence of any other apparent underlying cardiac disease underwent evaluation. Incessant tachycardia was present for 0.5 to 6.0 years (mean 2.1) in 7 patients. One patient had an ectopic atrial tachycardia and 7 patients had an accessory atrioventricular pathway that participated in reciprocating tachycardia. Six patients underwent surgery; the ectopic focus was ablated in 1 patient and an accessory pathway was divided in 5 patients. One patient underwent open ablation of the His bundle and 1 patient underwent closed-chest ablation of the atrioventricular conduction system. Myocardial biopsy specimens were obtained from 5 patients, none of which yielded a specific diagnosis. Pretreatment radionuclide angiography demonstrated a mean ejection fraction (EF) of 19 ± 9% (range 10 to 35%). Following tachycardia control a marked improvement in LV function was noted in 6 of 8 patients at rest and in 1 additional patient during exercise. The EF increased to 33 ± 17% (range 16 to 56%) an average of 8 days after treatment and to 45 ± 15% (range 22 to 67%) at late follow-up 3.5 ± 40 months (mean 17) later (p < 0.005). Seven patients remain asymptomatic 11 to 40 months (mean 22) after the corrective procedure and have resumed normal activities. These findings suggest that chronic uncontrolled tachycardia may result in significant LV dysfunction, which is reversible in some cases after control of the arrhythmia.

References (42)

  • A Righetti et al.

    Intra-ventricular septal motion and left ventricular function after coronary artery bypass surgery

    Am J Cardiol

    (1977)
  • HR Phillips et al.

    Serial changes in left ventricular ejection fraction in the early hours after aortocoronary bypass grafting

    Chest

    (1983)
  • DV Unverferth et al.

    Factors influencing the one year morbidity of bilateral cardiomyopathy

    Am J Cardiol

    (1984)
  • PC Gillette et al.

    Treatment of atrial automatic tachycardias by ablation procedures

    JACC

    (1985)
  • HN Coleman et al.

    Congestive heart failure following chronic tachycardia

    Am Heart J

    (1971)
  • KA Reimer et al.

    Prolonged depletion of ATP and of the adenine nucleotide pool due to delayed resynthesis of adenine nucleotides following reversible myocardial ischemic injury in dogs

    J Mol Cell Cardiol

    (1981)
  • MI Ferrer et al.

    Some hemodynamic aspects of cardiac arrhythmias in man

    Am Heart J

    (1964)
  • A Benchimol et al.

    Hemodynamic consequences of atrial and ventricular arrhythmias in man

    Am Heart J

    (1960)
  • P Samet

    Hemodynamic sequelae of cardiac arrhythmias

    Circulation

    (1973)
  • BN Goldreyer et al.

    The hemodynamic effects of induced supraventricular tachycardia in man

    Circulation

    (1976)
  • P Wood

    Polyuria in paroxysmal tachycardia and paroxysmal atrial flutter and fibrillation

    Br Heart J

    (1963)
  • Cited by (461)

    • Premature atrial contraction induced cardiomyopathy: A case report

      2023, Indian Pacing and Electrophysiology Journal
    • Large Animal Models of Heart Failure: A Translational Bridge to Clinical Success

      2020, JACC: Basic to Translational Science
      Citation Excerpt :

      Because of the historical use of these models, we briefly highlight these approaches in the following sections. Originally reported in 1962 (117), a significant number of canine (118,119), swine (120,121), and ovine (122,123) models of pacing-induced HF have been developed and used in both acute and chronic experimental settings (references provided for historical context). Cardiac pacing using heart rates across a spectrum of 120 to 260 beats/min have been routinely shown to induce symptoms comparable to HFrEF, including decreased EF, ventricular dilation and decreased ventricular wall thickness, pulmonary involvement, increased plasma expression of biomarkers (e.g., natriuretic peptides), and neurohumoral activation.

    View all citing articles on Scopus

    This study was supported in part by U.S. Public Health Service Research Award HL07101 and Research Grants HL17670, HL07503, CA33541 from the National institutes of Health, Bethesda, Maryland.

    View full text